Ozmosi | Matuzumab Drug Profile

Product Description

Mechanisms of Action: EGFR Binder

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Non-Small-Cell Lung Cancer|Gastrointestinal Cancer|Esophageal Cancer|Colorectal Cancer|Adenocarcinoma

Phase 1: Gastrointestinal Cancer|Adenocarcinoma|Esophageal Cancer

Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
2006-000899-32	P2	Completed	Non-Small-Cell Lung Cancer	2009-06-05	2022-03-12	Treatments
MATRIX EG	P2	Completed	Gastrointestinal Cancer\|Esophageal Cancer	2008-07-31	2024-11-27
MAURICE	P2	Completed	Colorectal Cancer	2007-10-30	2022-03-12	Treatments
EMD 72000-031	P2	Completed	Non-Small-Cell Lung Cancer	2007-07-31	2019-03-22	Treatments
MATRIX E.G.	P2	Completed	Gastrointestinal Cancer\|Adenocarcinoma	2007-04-28	2025-06-14	Treatments
2006-000871-13	P2	Completed	Non-Small-Cell Lung Cancer	2006-10-30	2022-03-12	Treatments
EMD 72000-024	P1	Completed	Adenocarcinoma\|Esophageal Cancer\|Gastrointestinal Cancer	2006-05-01	2019-03-21	Treatments
2006-7041-83/hah	N/A	Withdrawn	Encephalomyelitis\|Chronic Pain	None

Recent News Events

Date	Type	Title
03/21/2023	PubMed	New Perspectives for Prosthetic Valve Endocarditis: Impact of Molecular Imaging by FISHseq Diagnostics.
11/15/2022	PubMed	Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies.
09/10/2022	PubMed	Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Matuzumab

Alternative Names: matuzumab Clinical Status: Inactive Latest Update: 2023-03-21 Latest Update Note: PubMed Publication